A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia

Published:2014-04 Issue:4 Volume:38 Page:430-434
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

DeAngelo Daniel J.,Neuberg Donna,Amrein Philip C.,Berchuck Jacob E.,Wadleigh Martha,Sirulnik L. Andres,Galinsky Ilene,Golub Todd,Stegmaier Kimberly,Stone Richard M.

Funder

Astra-Zeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference44 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Acute myeloid leukemia;Lowenberg;N Engl J Med,1999

3. Treatment of resistant acute myeloid leukemia;Schiller;Blood Rev,1991

4. Age and acute myeloid leukemia;Appelbaum;Blood,2006

5. Hematologic malignancies;Gilliland;Curr Opin Hematol,2001

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells;Cancer Research;2023-12-14

2. Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment;Hematology Reports;2023-05-24

3. Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia;Biomedicines;2022-11-22

4. A Case of Isolated Myeloid Sarcoma Associated With Germline EGFR T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels;Journal of Hematology;2022-04

5. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy;Acta Haematologica;2021-10-21